vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and SILVERCORP METALS INC (SVM). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $223.8M, roughly 1.3× SILVERCORP METALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -1.3%, a 97.6% gap on every dollar of revenue. Over the past eight quarters, SILVERCORP METALS INC's revenue compounded faster (87.6% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Silvercorp Metals Inc. (Silvercorp) is a Canadian-based, China-focused precious metals company engaged in the acquisition, exploration, and development of silver-containing properties.
ACAD vs SVM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $223.8M |
| Net Profit | $273.6M | $-2.9M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | -1.3% |
| Revenue YoY | 9.4% | — |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $223.8M | ||
| Q3 25 | $278.6M | — | ||
| Q2 25 | $264.6M | $72.2M | ||
| Q1 25 | $244.3M | — | ||
| Q4 24 | $259.6M | $172.5M | ||
| Q3 24 | $250.4M | $114.0M | ||
| Q2 24 | $242.0M | $60.0M | ||
| Q1 24 | $205.8M | — |
| Q4 25 | $273.6M | $-2.9M | ||
| Q3 25 | $71.8M | — | ||
| Q2 25 | $26.7M | $28.1M | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $143.7M | $42.1M | ||
| Q3 24 | $32.8M | $28.0M | ||
| Q2 24 | $33.4M | $13.2M | ||
| Q1 24 | $16.6M | — |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | — | ||
| Q2 25 | 12.2% | — | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 59.1% | 30.5% | ||
| Q3 24 | 12.6% | 30.7% | ||
| Q2 24 | 12.6% | 30.0% | ||
| Q1 24 | 7.4% | — |
| Q4 25 | 96.3% | -1.3% | ||
| Q3 25 | 25.8% | — | ||
| Q2 25 | 10.1% | 39.0% | ||
| Q1 25 | 7.8% | — | ||
| Q4 24 | 55.4% | 24.4% | ||
| Q3 24 | 13.1% | 24.5% | ||
| Q2 24 | 13.8% | 22.0% | ||
| Q1 24 | 8.0% | — |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.20 | — | ||
| Q1 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | — |
| Total Assets | $1.6B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — | ||
| Q1 24 | $204.7M | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $917.3M | — | ||
| Q2 25 | $822.4M | — | ||
| Q1 25 | $765.2M | — | ||
| Q4 24 | $732.8M | — | ||
| Q3 24 | $577.2M | — | ||
| Q2 24 | $516.7M | — | ||
| Q1 24 | $464.0M | — |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $976.9M | — | ||
| Q2 24 | $914.1M | — | ||
| Q1 24 | $855.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $107.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $107.9M | ||
| Q3 25 | $74.3M | — | ||
| Q2 25 | $64.0M | $40.0M | ||
| Q1 25 | $20.3M | — | ||
| Q4 24 | $40.4M | $81.3M | ||
| Q3 24 | $63.2M | $57.7M | ||
| Q2 24 | $25.0M | $28.9M | ||
| Q1 24 | $29.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | $33.8M | ||
| Q2 24 | — | $17.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | 29.6% | ||
| Q2 24 | — | 28.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | 21.0% | ||
| Q2 24 | — | 19.8% | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | 1.42× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | 1.93× | ||
| Q3 24 | 1.93× | 2.06× | ||
| Q2 24 | 0.75× | 2.19× | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
SVM
Segment breakdown not available.
